特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
210301

中国の血液製剤産業

China Blood Product Industry Report, 2020-2026

出版日: | 発行: ResearchInChina | ページ情報: 英文 160 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
中国の血液製剤産業
出版日: 2020年01月21日
発行: ResearchInChina
ページ情報: 英文 160 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中国では、国民医療保険システムによってカバーされる医薬品の大幅な調整がなされ、ほぼすべての血液製剤が臨床使用されるようになり、また国民医療保険システムからの医療費還付の範囲も拡大しています。2019年には、中国における血液製剤の製造本数が8,989万本に達し、前年比で21.6%の急増を記録しました。その内訳としては、ヒトアルブミンの生産本数は年間ベースで17.2%増加し、全体の58.9%を占めています。狂犬病免疫グロブリンは42.9%増加し、全体の13.6%を占めています。静脈注射用ヒト免疫グロブリン(pH4)のシェアは全体の13%で、前年比で14.1%の増加となっています。

当レポートでは、中国の血液製剤産業について調査し、産業の概要、中国市場の動向、製品セグメント別の分析、主要企業、今後の発展予測などについて、体系的な情報を提供しています

第1章 血液製剤

  • 定義
  • 分類
  • 遺伝子組み換え血液製剤
  • 産業チェーン
  • 特徴

第2章 中国の血液製剤市場

  • 指針
  • 現状
  • 市場構造
  • 供給と需要
    • 供給
    • 需要
  • 市場規模
  • 競合パターン

第3章 中国の血液製剤市場:セグメント別

  • ヒトアルブミン
  • 静脈注射用ヒト免疫グロブリン (pH4)
  • 血液凝固第VII因子
  • B型肝炎免疫グロブリン
  • ヒト免疫グロブリン
  • ヒトプロトロンビン複合体
  • 破傷風免疫グロブリン
  • 狂犬病免疫グロブリン

第4章 主要企業

  • China Biologic Products(CBPO)
  • Hualan Biological Engineering Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Beijing Tiantan Biological Products
  • Guangdong Shuanglin Bio-Pharmacy
  • Jiangxi Boya Bio-Pharmaceutical
  • Weiguang Biological Products
  • Beijing Bohui Innovation Technology
  • Wuhan ZhongyuanRuide Biological Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Green Cross China
  • Nanyue Biopharming Corporation Ltd.

第5章 概要と予測

図表

Selected Charts

  • Basic Components of Blood
  • Plasma Protein Separation Procedure
  • Classification and Effects of Blood Products
  • Comparison between Gene Recombinant Blood Products and Traditional Blood Products
  • Comparison of Recombinant Blood Products in China and Overseas
  • Blood Product Industry Chain
  • Time Length of Plasma Collection and Separation Process
  • Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
  • Production & Sales Cycle of Blood Products
  • Main Policies on China Blood Product Industry, 1986-2018
  • Development History of China Blood Product Industry
  • Comparison between China and the United States in Per Capita Consumption of Main Blood Products
  • Lot Release Volume of Major Blood Products in China, 2014-2019
  • Blood Product Structure in China (by Lot Release Volume), 2014-2019
  • Plasma Collection Policies in China vs. USA and European Countries
  • Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
  • Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2019
  • Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2019
  • Plasma Collection Volume and YoY Growth Rate in China, 2008-2019
  • Comparison of Blood Products Listed in National Medical Insurance Catalogue: 2017vs2009
  • Plasma Supply and Demand in China, 2015-2025E
  • Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
  • Market Size of China Blood Product Industry, 2010-2019
  • Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Dec. 2019
  • Main Products of Major Blood Product Manufacturing Enterprises in China
  • Revenue of Major Blood Product Enterprises in China, 2013-2019
  • Net Income of Major Blood Product Enterprises in China, 2013-2019
  • Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2019
  • Market Share of China Blood Product Industry (by Enterprise), 2018
  • Market Share of China Blood Product Industry (by Enterprise), 2019
  • Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2019
  • Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2019
  • Market Share of Human Albumin in China (by Lot Release Volume), 2018
  • Market Share of Human Albumin in China (by Lot Release Volume), 2019
  • Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2019
  • Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2018
  • Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2019
  • Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
  • Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2019
  • Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2018
  • Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2019
  • Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
  • Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China, as of 2019H1
  • Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Hepatitis B Immunoglobulin, 2019
  • Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2018
  • Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2019
  • Lot Release Volume of Human Immunoglobulin in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2019
  • Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2018
  • Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2019
  • Lot Release Volume of Human Prothrombin Complex in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2019
  • Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2018
  • Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2019
  • Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Tetanus Immunoglobulin, 2019
  • Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2018
  • Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2019
  • Cases, Deaths and Mortality of Rabies in China, 2013-2019
  • Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2019
  • Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2019
  • Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2018
  • Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2019
  • Product Line of CBPO
  • Equity Structure of China Biologic Products Holdings
  • Revenue and Operating Income of CBPO, 2014-2019
  • Revenue Breakdown of CBPO (by Product), 2012-2019
  • Revenue Structure of CBPO (by Product), 2012-2019
  • Gross Margin of CBPO, 2012-2019
  • R&D Costs and % of Total Revenue of CBPO, 2012-2019
  • CBPO's Products under Research and R&D Process by the end of 2018
  • Main R&D Pipeline Products of Beijing TianXinFu Medical Appliance
  • Lot Release Volume of Blood Products of CBPO, 2016-2019
  • Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Dec. 2019
  • Ownership Structure of Shandong Taibang Biological Products
  • Main Plasma Collection Stations of Shandong Taibang Biological Products as of Dec. 2019
  • Ownership Structure of Xi'an Huitian Blood Products
  • Main Plasma Collection Stations of Xi'an Huitian Blood Products as of Dec.2019
  • Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2019
  • Revenue and Net Income of Hualan Biological Engineering, 2013-2019
  • Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2019
  • Revenue Structure of Hualan Biological Engineering (by Product), 2013-2019
  • Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2019
  • R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2019
  • Category and Specification of Blood Products of Hualan Biological Engineering
  • Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2016-2018
  • Revenue of Blood Products of Hualan Biological Engineering, 2013-2019
  • Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2019
  • Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2019
  • Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2019
  • Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2019
  • Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2019
  • Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2019
  • Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2019
  • R&D Costs of Shanghai RAAS Blood Products, 2013-2019
  • Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
  • Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2016-2018
  • Revenue and Net Income of Tiantan Biological Products, 2013-2019
  • Revenue Breakdown of TIANTANBIO (by Product), 2013-2019
  • Revenue Structure of TIANTANBIO (by Product), 2013-2019
  • Gross Margin of TIANTANBIO (by Product), 2013-2018
  • R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2019
  • R&D Input of Major Projects of TIANTANBIO, 2018
  • Progress of Major R&D Projects of TIANTANBIO, by the End of 2018
  • TIANTANBIO's Major Blood Products Subsidiaries and Stake
  • Production and Sales of Main Blood Products of TIANTANBIO, 2018
  • Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2019
  • Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2019
  • Revenue and Net Income of Shuanglin Bio-Pharmacy, 2013-2019
  • Gross Margin of Shuanglin Bio-Pharmacy, 2013-2019
  • R&D Costs and % of Total Revenue of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
  • Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
  • Production, Inventory and Sales of Main Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
  • Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2019
  • Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
  • Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
  • Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
  • Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
  • Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
  • Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2018
  • Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
  • R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
  • Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2018
  • Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2019
  • Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2019
  • Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2019
  • Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2019
  • Gross Margin of Shenzhen Weiguang Biological Products, 2014-2019
  • Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2019
  • R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2019
  • Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2019H1
  • Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2019
  • Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2018
  • Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2016-2018
  • Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2019H1
  • Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2019
  • Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2019
  • Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2019
  • Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2019
  • Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2019
  • R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2019
  • Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, 2019H1
  • Major Blood Products of Beijing Bohui Innovation Technology
  • Financials of Beijing Bohui Innovation Technology, 2017-2019
  • Lot Release Volume of Blood Products of Hebei Da'an Pharmaceutical, 2016-2019
  • Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2019
  • Development Course of Zhongyuan Ruide Biological Products
  • Financial Data of Zhongyuan Ruide, 2014-2017
  • Plasmapheresis Centers of Wuhan ZhongyuanRuide Biological Products, as of Dec.2019
  • Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2019
  • Development History of Sichuan Yuanda Shuyang Pharmaceutical
  • Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
  • Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
  • Plasma Collection Stations of Shanxi Kangbao Biological Product as of Dec. 2019
  • Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2019
  • Plasma Collection Stations of Green Cross China as of Jan. 2019
  • Lot Release Volume of Blood Products of Green Cross China, 2016-2019
  • Plasmapheresis Centers of Nanyue Biopharming, as of Dec.2019
  • Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
  • Market Size of Blood Products in China, 2018-2026E
  • M&A Cases of Foreign Blood Product Companies
  • M&A Cases in China Blood Product Industry, 2008-2019
  • Plasma Collection Volume and YoY Change in China, 2018-2026E
  • R&D Investment of Major Chinese Blood Product Enterprises, 2014-2019
  • Population Aged above 60 as a Percentage of Total Population in China, 2009-2018
目次

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimbursement from the national medical insurance system. In 2019, the lot release of blood products in China increased further and reached 89.89 million bottles with a year-on-year surge of 21.6%.

Elaborately, the lot release of human albumin rose 17.2% on an annualized basis, making up 58.9%; that of human rabies immunoglobulin soared by 42.9% and accounted for 13.6%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 13% in the total showed a year-on-year increase of 14.1%; and that of human tetanus immunoglobulin surged by 76.7% and occupied 6.9%.

Other products had small shares, such as human fibrinogen, three kinds of special immunoglobulin, human prothrombin complex, human coagulation factor VIII, particularly coagulation factor category as the lifesaving drug to the victims of hemophilia are often in short supply largely because of the shortage of plasma raw materials domestically as well as the low utilization of plasma.

As the prices of blood products are decontrolled and new plasma stations accelerate to be constructed in recent years, plasma collection in China has been growing year after year, reaching 8,600 tons or more in 2018 with a year-on-year increase of 7.5%. Of all, Beijing Tiantan Biological Products Co., Ltd in possession of 57 plasma stations ranked first by plasma collection up to 1,568.7 tons, a 16.5% share of the total, and its production efficiency gets improved significantly after an asset restructuring.

There are now about thirty blood product enterprises in China, but they are small-sized without rich product portfolios. The industry desires to be concentrated. It is starting from 2008 that the leading players staged mergers and acquisitions and have been developing apace mainly through M&A whilst independently building plasma stations. Meanwhile, some influential companies have turned their attention to overseas resources and good mode and have been actively exploring overseas markets through acquisitions and introducing state-of-the-art technologies from abroad. Undoubtedly, the Chinese market of blood products will get ever concentrated.

What's more, leading competitors beef up research and development of new products successively and strive to improve comprehensive utilization of plasma. A case in point is the coagulation factorVIII. Only a few Chinese companies such as China Biologic Products Holdings, Inc., Hualan Biological Engineering Co., Ltd., Shanghai RAAS Blood Products Co., Ltd and Green Cross China are competent to produce the coagulation factorVIII, but the peers including Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Southern Shuanglin Bio-Pharmacy Co., Ltd. (formerly known as Zhenxing Biopharmaceutical & Chemical Co., Ltd.), Wuhan ZhongyuanRuide Biological Products Co., Ltd., Beijing Bohui Innovation Technology Co., Ltd., Shenzhen Weiguang Biological Products Co., Ltd and Nanyue Biopharming Co., Ltd. are chasing hard and sparing no efforts in the development of the coagulation factorVIII.

‘China Blood Product Industry Report, 2020-2026’ covers the following:

  • Blood product market (policy, status quo, market structure, supply & demand, market size and competitive pattern);
  • Blood product market segments (development, bidding price, competitive landscape);
  • 13 blood product companies (operation, revenue structure, gross margin and blood product business, etc.);
  • Summary and forecast.

Table of Contents

1. Blood Products

  • 1.1. Definition
  • 1.2. Classification
  • 1.3. Recombinant Blood Products
  • 1.4. Industry Chain
  • 1.5. Features

2. China Blood Product Market

  • 2.1. Policies
  • 2.2. Status Quo
  • 2.3. Market Structure
  • 2.4. Market Supply and Demand
    • 2.4.1. Supply
    • 2.4.2. Demand
  • 2.5. Market Size
  • 2.6. Competition Pattern

3. China Blood Product Market Segments

  • 3.1. Human Albumin
    • 3.1.1. Development Status
    • 3.1.2. Bid Price
    • 3.1.3. Market Structure
    • 3.1.4. Competition Pattern
    • 3.1.5. Prospects
  • 3.2. Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1. Development Status
    • 3.2.2. Bid Price
    • 3.2.3. Competition Pattern
    • 3.2.4. Prospects
  • 3.3. Coagulation Factor VIII
    • 3.3.1. Development Status
    • 3.3.2. Bid Price
    • 3.3.3. Competition Pattern
    • 3.3.4. Prospects
  • 3.4. Hepatitis B Immunoglobulin
    • 3.4.1. Development Status
    • 3.4.2. Bid Price
    • 3.4.3. Competition Pattern
  • 3.5. Human Immunoglobulin
    • 3.5.1. Development Status
    • 3.5.2. Bid Price
    • 3.5.3. Competition Pattern
  • 3.6. Human Prothrombin Complex
    • 3.6.1. Development Status
    • 3.6.2. Bid Price
    • 3.6.3. Competition Pattern
  • 3.7. Tetanus Immunoglobulin
    • 3.7.1. Development Status
    • 3.7.2. Bid Price
    • 3.7.3. Competition Pattern
  • 3.8. Human Rabies Immunoglobulin
    • 3.8.1. Development Status
    • 3.8.2. Bid Price
    • 3.8.3. Competition Pattern

4. Major Enterprises

  • 4.1. China Biologic Products (CBPO)
    • 4.1.1. Profile
    • 4.1.2. Operation
    • 4.1.3. Revenue Structure
    • 4.1.4. Gross Margin
    • 4.1.5. R&D Investment
    • 4.1.6. Blood Products Business
    • 4.1.7. Guizhou Taibang Biological Products Co., Ltd.
    • 4.1.8. Shandong Taibang Biological Products Co., Ltd.
    • 4.1.9. Xi'an Huitian Blood Products Co., Ltd.
  • 4.2. Hualan Biological Engineering Co., Ltd.
    • 4.2.1. Profile
    • 4.2.2. Operation
    • 4.2.3. Revenue Structure
    • 4.2.4. Gross Margin
    • 4.2.5. R&D Investment
    • 4.2.6. Blood Products Business
    • 4.2.7. Development Strategy
  • 4.3. Shanghai RAAS Blood Products Co., Ltd.
    • 4.3.1. Profile
    • 4.3.2. Operation
    • 4.3.3. Revenue Structure
    • 4.3.4. Gross Margin
    • 4.3.5. R&D Investment
    • 4.3.6. Blood Products Business
    • 4.3.7. Development Strategy
  • 4.4. Beijing Tiantan Biological Products
    • 4.4.1. Profile
    • 4.4.2. Operation
    • 4.4.3. Revenue Structure
    • 4.4.4. Gross Margin
    • 4.4.5. R&D Investment
    • 4.4.6. Blood Products Business
    • 4.4.7. Chengdu Rongsheng
  • 4.5. Guangdong Shuanglin Bio-Pharmacy
    • 4.5.1. Profile
    • 4.5.2. Operation
    • 4.5.3. Gross Margin
    • 4.5.4. R&D Investment
    • 4.5.5. Blood Products Business
    • 4.5.6. Development Strategy
  • 4.6. Jiangxi Boya Bio-Pharmaceutical
    • 4.6.1. Profile
    • 4.6.2. Operation
    • 4.6.3. Revenue Structure
    • 4.6.4. Gross Margin
    • 4.6.5. R&D Investment
    • 4.6.6. Blood Products Business
    • 4.6.7. Development Strategy
  • 4.7. Weiguang Biological Products
    • 4.7.1. Profile
    • 4.7.2. Operation
    • 4.7.3. Revenue Structure
    • 4.7.4. Gross Margin
    • 4.7.5. R&D Investment
    • 4.7.6. Blood Products Business
    • 4.7.7. Development Strategy
  • 4.8. Beijing Bohui Innovation Technology
    • 4.8.1. Profile
    • 4.8.2. Operation
    • 4.8.3. Revenue Structure
    • 4.8.4. Gross Margin
    • 4.8.5. R&D Investment
    • 4.8.6. Blood Products Business
    • 4.8.7. Development Strategy
  • 4.9. Wuhan ZhongyuanRuide Biological Products Co., Ltd.
    • 4.9.1. Profile
    • 4.9.2. Operation
    • 4.9.3. Blood Products Business
  • 4.10. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.10.1. Profile
    • 4.10.2. Blood Products Business
  • 4.11. Shanxi Kangbao Biological Product Co., Ltd.
    • 4.11.1. Profile
    • 4.11.2. Blood Products Business
  • 4.12. Green Cross China
    • 4.12.1. Profile
    • 4.12.2. Blood Products Business
  • 4.13. Nanyue Biopharming Corporation Ltd.
    • 4.13.1. Profile
    • 4.13.2. Blood Products Business

5. Summary and Forecast

  • 5.1. Summary
  • 5.2. Development Trend
    • 5.2.1. The Industry Continues to Boom
    • 5.2.2. Industry Integration Speeds Up, Concentration Rises Further
    • 5.2.3. Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
    • 5.2.4. Plasma Volume Increases Progressively
    • 5.2.5. Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise
    • 5.2.6. Downstream Demand Stimulates the Development of the Industry
    • 5.2.7. Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.